---
schema_version: "secwatch.filing_event.v1"
accession: "0001113148-23-000014"
form_type: "8-K"
ticker: null
cik: "0001113148"
company_name: "INFINITY PHARMACEUTICALS, INC."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:36:08.218632+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Infinity Pharma receives Nasdaq deficiency for Minimum MVPHS; faces multiple delisting risks

## Summary
- Nasdaq letter on Sep 5: MVPHS < $15M for prior 30 consecutive business days.
- Company has 180 calendar days, until Mar 4, 2024, to regain compliance.
- Already out of compliance with bid-price (Rule 5450(a)(1)) and MVLS (Rule 5450(b)(2)(A)) listing rules.
- Existing appeal of prior delisting determination is pending before Nasdaq Panel.
- Failure to cure MVPHS could lead to delisting or transfer to Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001113148-23-000014
- form_type: 8-K
- cik: 0001113148
- company_name: INFINITY PHARMACEUTICALS, INC.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000014/0001113148-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000014/infi-20230905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001113148-23-000014
- JSON: https://secwatch.observer/filing/0001113148-23-000014.json
- Plain text: https://secwatch.observer/filing/0001113148-23-000014.txt

## Key facts
- Listing & Compliance Notices
  INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(C), 5810(c)(3)(D)
  source text: September 5, 2023, Infinity Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”) for continued listing on The Nasdaq Global Select Market, as the market value of the Company’s publicly held shares was less than $15,000,000 for each of the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(D
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000014/0001113148-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.